Growth Metrics

Innoviva (INVA) Cash & Current Investments (2009 - 2026)

Innoviva posted quarterly Cash & Current Investments of $603.1 million for Q1 2026, up 89.0% year-on-year from $319.1 million in Q1 2025, and up 9.46% on a QoQ basis from $550.9 million in Q4 2025.

Innoviva (INVA) has 18 years of Cash & Current Investments data on file, last reported at $603.1 million in Q1 2026.

  • For the quarter ending Q1 2026, Cash & Current Investments rose 89.0% year-over-year to $603.1 million; the trailing twelve-month figure through Mar 2026 stood at $603.1 million (up 89.0% YoY), and the FY2025 full-year result was $550.9 million, up 80.66% from the prior year.
  • Cash & Current Investments for Q1 2026 stood at $603.1 million, up from $550.9 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $603.1 million in Q1 2026 and bottomed at $144.0 million in Q1 2023.
  • The 5-year median for Cash & Current Investments is $283.6 million (2022), against an average of $299.5 million.
  • The widest annual swing landed in 2022, when Cash & Current Investments jumped 555.45%; it then plunged 40.21% in 2023.
  • A 5-year view of Cash & Current Investments shows it stood at $291.0 million in 2022, then plunged by 33.51% to $193.5 million in 2023, then jumped by 57.59% to $305.0 million in 2024, then jumped by 80.66% to $550.9 million in 2025, then advanced by 9.46% to $603.1 million in 2026.
  • The last three Cash & Current Investments figures came in at $603.1 million (Q1 2026), $550.9 million (Q4 2025), and $476.5 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Current Investments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 2.13 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 32.30 Mn
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 286.70 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 61.46 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 2.77 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 7.25 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - 18.44 Mn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 8.75 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 3.01 Bn
10 Innoviva 1.60 Bn 992.84 Mn 75.83 Mn 603.09 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 603.09 Mn
Dec 31, 2025 550.94 Mn
Sep 30, 2025 476.51 Mn
Jun 30, 2025 397.53 Mn
Mar 31, 2025 319.09 Mn
Dec 31, 2024 304.96 Mn
Sep 30, 2024 260.63 Mn
Jun 30, 2024 217.00 Mn
Mar 31, 2024 178.36 Mn
Dec 31, 2023 193.51 Mn
Sep 30, 2023 180.00 Mn
Jun 30, 2023 173.03 Mn
Mar 31, 2023 144.05 Mn
Dec 31, 2022 291.05 Mn
Sep 30, 2022 301.07 Mn
Jun 30, 2022 283.58 Mn
Mar 31, 2022 216.80 Mn
Dec 31, 2021 201.53 Mn
Sep 30, 2021 135.12 Mn
Jun 30, 2021 43.27 Mn
Mar 31, 2021 282.89 Mn
Dec 31, 2020 246.49 Mn
Sep 30, 2020 479.19 Mn
Jun 30, 2020 417.15 Mn
Mar 31, 2020 383.95 Mn
Dec 31, 2019 350.85 Mn
Sep 30, 2019 297.20 Mn
Jun 30, 2019 249.66 Mn
Mar 31, 2019 192.18 Mn
Dec 31, 2018 114.91 Mn
Sep 30, 2018 55.48 Mn
Jun 30, 2018 107.54 Mn
Mar 31, 2018 56.46 Mn
Dec 31, 2017 129.08 Mn
Sep 30, 2017 168.19 Mn
Jun 30, 2017 135.63 Mn
Mar 31, 2017 169.81 Mn
Dec 31, 2016 150.43 Mn
Sep 30, 2016 148.97 Mn
Jun 30, 2016 153.87 Mn
Mar 31, 2016 168.19 Mn
Dec 31, 2015 187.28 Mn
Sep 30, 2015 206.19 Mn
Jun 30, 2015 229.26 Mn
Mar 31, 2015 251.14 Mn
Dec 31, 2014 240.50 Mn
Sep 30, 2014 263.11 Mn
Jun 30, 2014 334.48 Mn
Mar 31, 2014 370.92 Mn
Dec 31, 2013 465.13 Mn
Sep 30, 2013 506.15 Mn
Jun 30, 2013 443.01 Mn
Mar 31, 2013 459.06 Mn
Dec 31, 2012 248.49 Mn
Sep 30, 2012 273.44 Mn
Jun 30, 2012 295.49 Mn
Mar 31, 2012 200.16 Mn
Dec 31, 2011 240.92 Mn
Sep 30, 2011 265.17 Mn
Jun 30, 2011 283.89 Mn
Mar 31, 2011 147.87 Mn
Dec 31, 2010 309.60 Mn
Sep 30, 2010 63.10 Mn
Jun 30, 2010 69.72 Mn
Dec 31, 2009 47.54 Mn